33173-27-2

Usage

Uses

Used in Organic Synthesis:
(S)-3-(4-nitrophenyl)-2-hydroxypropionic acid is used as a building block in organic synthesis for the creation of more complex molecules. Its 4-nitrophenyl group provides electron-withdrawing capabilities, making it a useful component in reactions that necessitate strong electrophilic substituents.
Used in Chemical Research:
In chemical research, (S)-3-(4-nitrophenyl)-2-hydroxypropionic acid serves as an essential compound for studying various reaction mechanisms and exploring new synthetic pathways. Its unique structure allows researchers to investigate its properties and reactivity, contributing to the advancement of chemical knowledge.
Used in Pharmaceutical Research:
(S)-3-(4-nitrophenyl)-2-hydroxypropionic acid is used as a potential candidate in pharmaceutical research for drug discovery and development. Its possible biological activities make it an interesting starting point for the design and synthesis of new therapeutic agents.
Used in Drug Delivery Systems:
In the pharmaceutical industry, (S)-3-(4-nitrophenyl)-2-hydroxypropionic acid may be employed in the development of novel drug delivery systems. Its unique properties could be harnessed to improve the delivery, bioavailability, and therapeutic outcomes of various drugs, particularly in the context of targeted drug delivery and controlled release applications.
Used in Analytical Chemistry:
(S)-3-(4-nitrophenyl)-2-hydroxypropionic acid can be utilized in analytical chemistry as a reagent or a reference compound for the development and validation of analytical methods. Its distinct chemical and physical properties make it suitable for various applications, such as chromatography, spectroscopy, and titration techniques.

Upstream product

• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 949-99-5 4-nitro-3-phenyl-L-alanine 

Downstream Products

• 66592-67-4 L-(-)-p-Aminophenyl-milchsaeure 
• 929083-97-6 L-(-)-3-(4-nitrophenyl)lactic acid methyl ester 
• 15482-94-7 rac-3-(4-nitrophenyl)-2-hydroxypropionic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents

A series of novel isochroman mono-carboxylic acid derivatives were synthesized, characterized and evaluated for their ability to inhibit protein tyrosine phosphatase 1B (PTP1B) in vitro in order to use them as potential anti-diabetic agents. Analysis of structure-activity relationships led to the identification of potent compound 4n which inhibited PTP1B with IC50 value of 51.63 ± 0.91 nM. In general, high potency was associated with a dithiolane ring with a spacer of five carbons to the isochroman ring. Compound 4n has been selected for in vivo evaluation as drug candidate for anti-diabetic activity.

BASIC SALTS AND MONOHYDRATES OF CERTAIN ALPHA, BETA-PROPRIONIC ACID DERIVATIVE

The invention provides novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid, including Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propilamino}phenyl] proprionic acid monohydrate, Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid, and (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid monohydrate. Various aspects and embodiments are included. Compositions containing novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid are also provided.

Biocatalytic racemization of (hetero)aryl-aliphatic α- hydroxycarboxylic acids by Lactobacillus spp. proceeds via an oxidation-reduction sequence

The biocatalytic racemization of a range of (hetero)aryl- and (di)aryl-aliphatic α-hydroxycarboxylic acids has been achieved by using whole resting cells of Lactobacillus spp. The essentially mild (physiological) reaction conditions ensure the suppression of undesired side reactions, such as elimination, decomposition or condensation. Cofactor/inhibitor studies using a cell-free extract of Lactobacillus paracasei DSM 20207 reveal that the addition of redox cofactors (NAD+/NADH) leads to a distinct increase in the racemization rate, while strong inhibition is observed in the presence of Thio-NAD+, which suggests that the racemization proceeds by an oxidation-reduction sequence rather than involvement of a "racemase" enzyme. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds.

Basic salts and monohydrates of certain alpha, beta-propionic acid derivative

The invention provides novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid, including Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate, Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino} phenyl] propionic acid, and (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate. Various aspects and embodiments are included. Compositions containing novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino}phenyl] propionic acid are also provided.

Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.